News
Watch
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Health Systems|

Pharmacy Technician|

Opinion|Videos|October 29, 2026

NMOSD Underdiagnosed and Overlooked: A Neurologist and Pharmacist on the Path to Better Care Video

Pharmacy Times Medcast

Episodes in this series

EP. 1 Key Considerations for the Effective Utilization of RSV Vaccines

Ashley Pugh, PharmD, and Lauren Angelo, PharmD, MBA

EP. 2 Key Things to Consider for the Effective Utilization of RSV Vaccines

EP. 3 Empowering Pharmacists: Navigating Pediatric OTC Medications and Building Trust with Parents

Trisha Winroth, PharmD, and Ashly McPhillips, PharmD

EP. 4 Empowering Pharmacists: Navigating Pediatric OTC Medications and Building Trust With Parents

1 KOL is featured in this series.

EP. 5 Behind the Counter: Mastering Pseudoephedrine and Other Restricted OTC Medications

2 KOLs are featured in this series.

EP. 6 Enfortumab Vedotin and the Evolving Landscape of Bladder Cancer Care: A Pharmacist’s Guide to ADCs, Combination Therapy, and Expanding Clinical Engagement

EP. 7 Podcast: Enfortumab Vedotin and the Evolving Landscape of Bladder Cancer Care: A Pharmacist’s Guide to ADCs, Combination Therapy, and Expanding Clinical Engagement

EP. 7 Podcast: Enfortumab Vedotin and the Evolving Landscape of Bladder Cancer Care: A Pharmacist’s Guide to ADCs, Combination Therapy, and Expanding Clinical Engagement

EP. 8 Podcast: Targeting CSF1R in TGCT: Evaluating the Evidence and Empowering Pharmacist-Led Care

EP. 9 Navigating a Shifting Landscape at the Pharmacy Counter Deck Podcast

2 KOLs are featured in this series.

EP. 10 Navigating a Shifting Landscape at the Pharmacy Counter

2 KOLs are featured in this series.

EP. 11 NMOSD Underdiagnosed and Overlooked: A Neurologist and Pharmacist on the Path to Better Care Video

EP. 12 NMOSD Underdiagnosed and Overlooked: A Neurologist and Pharmacist on the Path to Better Care

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related to this article

FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer

October 26th, 2026

FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer

The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.

Trending on Pharmacy Times

PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease

Kidney Week 2026: Pharmacists' Growing Role in Kidney Care

Cystatin C and the Future of Kidney Function Assessment

The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment

Chemotherapy-Free Pembrolizumab Extends PFS in First-Line dMMR Endometrial Cancer